320 related articles for article (PubMed ID: 18004406)
1. Viral vector-based prime-boost immunization regimens: a possible involvement of T-cell competition.
de Mare A; Lambeck AJ; Regts J; van Dam GM; Nijman HW; Snippe H; Wilschut J; Daemen T
Gene Ther; 2008 Mar; 15(6):393-403. PubMed ID: 18004406
[TBL] [Abstract][Full Text] [Related]
2. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
3. Heterologous prime-boost immunizations with a virosomal and an alphavirus replicon vaccine.
Walczak M; de Mare A; Riezebos-Brilman A; Regts J; Hoogeboom BN; Visser JT; Fiedler M; Jansen-Dürr P; van der Zee AG; Nijman HW; Wilschut J; Daemen T
Mol Pharm; 2011 Feb; 8(1):65-77. PubMed ID: 20825215
[TBL] [Abstract][Full Text] [Related]
4. Role of T cell competition in the induction of cytotoxic T lymphocyte activity during viral vector-based immunization regimens.
Lambeck AJ; Nijman HW; Hoogeboom BN; Regts J; de Mare A; Wilschut J; Daemen T
Vaccine; 2010 Jun; 28(26):4275-82. PubMed ID: 20434555
[TBL] [Abstract][Full Text] [Related]
5. Genetic immunization against cervical carcinoma: induction of cytotoxic T lymphocyte activity with a recombinant alphavirus vector expressing human papillomavirus type 16 E6 and E7.
Daemen T; Pries F; Bungener L; Kraak M; Regts J; Wilschut J
Gene Ther; 2000 Nov; 7(21):1859-66. PubMed ID: 11110419
[TBL] [Abstract][Full Text] [Related]
6. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector.
Juillard V; Villefroy P; Godfrin D; Pavirani A; Venet A; Guillet JG
Eur J Immunol; 1995 Dec; 25(12):3467-73. PubMed ID: 8566039
[TBL] [Abstract][Full Text] [Related]
7. Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization.
Daemen T; Riezebos-Brilman A; Regts J; Dontje B; van der Zee A; Wilschut J
Antivir Ther; 2004 Oct; 9(5):733-42. PubMed ID: 15535411
[TBL] [Abstract][Full Text] [Related]
8. Prime-boost vaccination using recombinant Mycobacterium bovis BCG and recombinant vaccinia virus DIs harboring HIV-1 CRF01_AE gag in mice: influence of immunization routes.
Promkhatkaew D; Matsuo K; Pinyosukhee N; Thongdeejaroen W; Leang-Aramgul P; Sawanpanyalert P; Warachit P
Southeast Asian J Trop Med Public Health; 2009 Mar; 40(2):273-81. PubMed ID: 19323012
[TBL] [Abstract][Full Text] [Related]
9. Efficient expansion of HIV-1-specific T cell responses by homologous immunization with recombinant Semliki Forest virus particles.
Sundbäck M; Douagi I; Dayaraj C; Forsell MN; Nordström EK; McInerney GM; Spångberg K; Tjäder L; Bonin E; Sundström M; Liljeström P; Karlsson Hedestam GB
Virology; 2005 Oct; 341(2):190-202. PubMed ID: 16098555
[TBL] [Abstract][Full Text] [Related]
10. Augmentation of alphavirus vector-induced human papilloma virus-specific immune and anti-tumour responses by co-expression of interleukin-12.
Riezebos-Brilman A; Regts J; Chen M; Wilschut J; Daemen T
Vaccine; 2009 Jan; 27(5):701-7. PubMed ID: 19041356
[TBL] [Abstract][Full Text] [Related]
11. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour.
Herd KA; Harvey T; Khromykh AA; Tindle RW
Virology; 2004 Feb; 319(2):237-48. PubMed ID: 14980484
[TBL] [Abstract][Full Text] [Related]
12. Prime-boost immunization using alphavirus replicon and adenovirus vectored vaccines induces enhanced immune responses against classical swine fever virus in mice.
Zhao HP; Sun JF; Li N; Sun Y; Wang Y; Qiu HJ
Vet Immunol Immunopathol; 2009 Oct; 131(3-4):158-66. PubMed ID: 19411115
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
[TBL] [Abstract][Full Text] [Related]
14. Induction of human papilloma virus E6/E7-specific cytotoxic T-lymphocyte activity in immune-tolerant, E6/E7-transgenic mice.
Riezebos-Brilman A; Regts J; Freyschmidt EJ; Dontje B; Wilschut J; Daemen T
Gene Ther; 2005 Sep; 12(18):1410-4. PubMed ID: 15843807
[TBL] [Abstract][Full Text] [Related]
15. Induction of cytotoxic T lymphocyte activity by immunization with recombinant Semliki Forest virus: indications for cross-priming.
Huckriede A; Bungener L; Holtrop M; de Vries J; Waarts BL; Daemen T; Wilschut J
Vaccine; 2004 Mar; 22(9-10):1104-13. PubMed ID: 15003637
[TBL] [Abstract][Full Text] [Related]
16. A vaccination strategy consisting of Semliki-Forest-virus (SFV) DNA prime and fowlpox-virus boost significantly protects mice from a recombinant (HIV-1) vaccinia-virus infection.
Quintana-Vázquez D; Vázquez-Blomquist DM; Galbán Rodríguez E; Herrera Buch AM; Duarte Cano CA
Biotechnol Appl Biochem; 2005 Feb; 41(Pt 1):59-66. PubMed ID: 15099194
[TBL] [Abstract][Full Text] [Related]
17. Rapid memory CD8+ T-lymphocyte induction through priming with recombinant Mycobacterium smegmatis.
Hovav AH; Cayabyab MJ; Panas MW; Santra S; Greenland J; Geiben R; Haynes BF; Jacobs WR; Letvin NL
J Virol; 2007 Jan; 81(1):74-83. PubMed ID: 17050608
[TBL] [Abstract][Full Text] [Related]
18. DNA prime/protein boost immunization against HIV clade C: safety and immunogenicity in mice.
Rasmussen RA; Ong H; Kittel C; Ruprecht CR; Ferrantelli F; Hu SL; Polacino P; McKenna J; Moon J; Travis B; Ruprecht RM
Vaccine; 2006 Mar; 24(13):2324-32. PubMed ID: 16406147
[TBL] [Abstract][Full Text] [Related]
19. DNA immunization followed by a viral vector booster in a Chlamydia pneumoniae mouse model.
Penttilä T; Tammiruusu A; Liljeström P; Sarvas M; Mäkelä PH; Vuola JM; Puolakkainen M
Vaccine; 2004 Sep; 22(25-26):3386-94. PubMed ID: 15308363
[TBL] [Abstract][Full Text] [Related]
20. Immunization strategy against cervical cancer involving an alphavirus vector expressing high levels of a stable fusion protein of human papillomavirus 16 E6 and E7.
Daemen T; Regts J; Holtrop M; Wilschut J
Gene Ther; 2002 Jan; 9(2):85-94. PubMed ID: 11857066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
